Literature DB >> 23341111

[New guidelines on functional and somatoform disorders].

Constanze Hausteiner-Wiehle1, Rainer Schäfert, Heribert Sattel, Joram Ronel, Markus Herrmann, Winfried Häuser, Alexandra Martin, Peter Henningsen.   

Abstract

The S3 guideline "Dealing with patients with non-specific, functional and somatoform bodily symptoms" emphasizes the similarities in the management of the manifold manifestations of so called "medically unexplained symptoms" and gives recommendations for a stepped and collaborative diagnostic and therapeutic approach in all subspecialties and all levels of health care. It has a special focus on recommendations regarding attitude, physician-patient-relationship, communication, the parallelization of somatic and psychosocial diagnostics and a stepped therapeutic approach. The "Evidence-based guideline psychotherapy in somatoform disorders and associated syndromes" provides a differentiated analysis of the current evidence regarding the effectiveness of various psychotherapeutic interventions for the most relevant manifestations of functional and somatoform disorders. In combination, both guidelines pose important advances for treatment quality in Germany, but also illustrate remarkable structural and research deficits. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2013        PMID: 23341111     DOI: 10.1055/s-0032-1323743

Source DB:  PubMed          Journal:  Psychother Psychosom Med Psychol        ISSN: 0937-2032


  2 in total

Review 1.  [Internal medicine between soma and psyche : Functional bodily complaints and depressive disorders in outpatient care].

Authors:  Ivo G Grebe
Journal:  Internist (Berl)       Date:  2020-01       Impact factor: 0.743

2.  Differentiating cerebral ischemia from functional neurological symptom disorder: a psychosomatic perspective.

Authors:  Carl E Scheidt; Kathrin Baumann; Michael Katzev; Matthias Reinhard; Sebastian Rauer; Michael Wirsching; Andreas Joos
Journal:  BMC Psychiatry       Date:  2014-05-29       Impact factor: 3.630

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.